SCHEMBL25846204

SCHEMBL25846204

CC(C)(N)Cc1ccc(CO)c(CO)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 2/20 0.47
HTR2A P28223 1/20 0.47
SLC6A4 P31645 1/20 0.47
HRH1 P35367 1/20 0.47
HTR2B P41595 1/20 0.47
CHRNA4 P43681 1/20 0.47
SLC6A3 Q01959 1/20 0.47
TAAR1 Q96RJ0 1/20 0.45
BLM P54132 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 2/20 0.38
POLB P06746 2/20 0.38
CYP3A4 P08684 2/20 0.38
MAPT P10636 2/20 0.38
HPGD P15428 2/20 0.38
ALOX15 P16050 2/20 0.38
HSD17B10 Q99714 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25751730 0.84 ESR1 (0.48) BLMKDM4EALDH1A1CYP1A2POLB
SCHEMBL25846208 0.81 ESR1 (0.35) SLC6A2HTR2ASLC6A4HRH1HTR2B
SCHEMBL25846222 0.81 CYP1A2 (0.62) SLC6A2TAAR1BLMKDM4EALDH1A1
SCHEMBL25846223 0.81 ESR1 (0.35) SLC6A2HTR2ASLC6A4HRH1HTR2B
SCHEMBL25846211 0.81 CYP3A4 (0.46) BLMKDM4EALDH1A1CYP1A2POLB
SCHEMBL25846210 0.77 ESR1 (0.37) VDRKLF10ACE2SHBGESR1
SCHEMBL2140136 0.74 SLC6A2 (0.57) SLC6A2HTR2ASLC6A4HRH1HTR2B
SCHEMBL29366879 0.74 EGFR (0.47) KDM4EMAPTHSD17B10EGFRRECQL
SCHEMBL63126 0.74 EGFR (0.47) KDM4EMAPTHSD17B10EGFRRECQL
SCHEMBL13953779 0.74 CNR1 (0.50) CYP3A4MAPTALOX15TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11702383-B2 Methods for producing D-α-methyldopa IMMUNOMOLECULAR THERAPEUTICS, INC. (US) 2023-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11702383-B2 Methods for producing D-α-methyldopa AMPD2, AMPD3, AMPD1 SLC6A2 476/4885HTR2A 54/4885SLC6A4 623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.